Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125183692 | 12518369 | 2 | F | 20160316 | 20160628 | 20160630 | 20160706 | EXP | CA-GILEAD-2016-0220676 | GILEAD | 39.00 | YR | A | F | Y | 0.00000 | 20160706 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125183692 | 12518369 | 1 | PS | EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | EMTRICITABINETENOFOVIR DISOPROXIL | 1 | Oral | 1 DF, UNK | 21752 | 1 | DF | TABLET | |||||||
| 125183692 | 12518369 | 2 | SS | DARUNAVIR | DARUNAVIR | 1 | Oral | 800 MG, QD | 0 | 800 | MG | QD | |||||||
| 125183692 | 12518369 | 3 | SS | RITONAVIR. | RITONAVIR | 1 | Oral | 100 MG, QD | 0 | 100 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125183692 | 12518369 | 1 | HIV infection |
| 125183692 | 12518369 | 2 | HIV infection |
| 125183692 | 12518369 | 3 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125183692 | 12518369 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125183692 | 12518369 | Abortion spontaneous | |
| 125183692 | 12518369 | Maternal exposure during pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |